Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer

Cardoso,  HJ; Vaz, CV; Correia, Sara; Figueira, Marília I; Marques, Ricardo; Baptista, Cláudio; Socorro, Sílvia

http://hdl.handle.net/10400.6/7665

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Paradoxical and contradictory effects of imatinib in two cell line.pdf		2.05 MB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Imatinib mesylate is a chemotherapeutic drug that inhibits the tyrosine kinase activity of c-KIT and has been successfully used to treat leukemias and some solid tumors. However, its application for treatment of hormone-refractory prostate cancer (HRPC) has shown modest effectiveness and did not follow the outcomes in cultured cells or animal models. Moreover, the molecular pathways by which imatinib induces cytotoxicity in prostate cancer cells are poorly characterized.